MACROCYCLES FOR DRUG DISCOVERY ONLINE LECTURE SERIES

We are bringing together world-leading experts to explore the frontiers of macrocycles in modern drug discovery!
 Join us online
1st Thursday every month at 17:00
(Berlin time, unless otherwise noted)
join us via Zoom Link:
https://tu-darmstadt.zoom-x.de/j/64384397721?pwd=0bWgCcqVS4PDAQckDQVER9wzcAsZu4.1

 Upcoming Lectures
06 November 2025: (Thursday)
17:00 Giulia Caron (Univeristy of Torino, IT):
Property-Based Drug Design: Principles and Adapting Ro5 Strategies to Macrocycles
17:45 Sereina Riniker (ETH Zurich, CH):
In Silico Exploration of Cyclic Peptides – Structure-Permeability Relationships

04 December 2025: (Thursday)
17:00 Adrian Whitty (Boston University, US):
What does a 'druglike macrocycle' look like
17:45 Andrei Yudin (University of Toronto, CA):
Strategic replacement of amino acid residues in macrocycles: Enabling iterative construction of novel scaffolds for drug discovery
 
05 Feburary 2026
17:00 Felix Hausch (Technical University Darmstadt, DE):
Cyclic linkerology – the art of closing ends
17:45 Nele-Johanna Hempel-Højgaard (NovoNordisk, DK):
Peptidic macrocycles – an upcoming modality
 
05 March 2026
17:00 Hiroaki Suga (University of Tokyo, JP):
Pseudonatural macrocycles
17:45 Frauke Pohlki (AbbVie, DE):
Macrocyclic MCL-1 Inhibitors
 
02 April 2026
13:00 Weibo Yang (Shanghai Institute of Materia Medica, Chinese Academy of Science, CN)
13:45 Ryuji Hayashi (Chugai, JP)
Orally Bioavailable Cyclic Peptide Drug Discovery Platform Targeting an Intracellular Protein
 
28 May 2026
17:00 Pierre-Luc Boudreault (University of Sherbrooke, CA):
Macrocycles as Next-Generation Non-Opioid Analgesics Targeting NTS2
17:45 tbd
------------------------------------------------------------------

Past Lectures
09 October 2025: (Thursday)
17:00 Scott Lokey (UC Santa Cruz, US):
Investigating Structure-permeability relationships in cyclic peptide scaffolds using mass-encoded libraries
17:45 Jan Kihlberg (Uppsala University, SE):
Macrocycles in Drug Discovery - Reaching intracellular difficult-to-drug targets